Breakthrough bacteraemia due to tigecycline-resistant escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis

Neil R.H. Stone*, Neil Woodford, David M. Livermore, Julia Howard, Rachel Pike, Shazad Mushtaq, Claire Perry, Susan Hopkins

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

35 Citations (Scopus)
Original languageEnglish
Article numberdkr337
Pages (from-to)2677-2678
Number of pages2
JournalJournal of Antimicrobial Chemotherapy
Issue number11
Publication statusPublished - Nov 2011

Bibliographical note

Funding Information:
N. W. has received research grants and conference support from most major pharmaceutical companies; none represents a conflict of interest with the content of this article. D. M. L. has received grants, speaking invitations and conference invitations from most major pharmaceutical companies and holds shares in GSK, Pfizer, AstraZeneca, Merck, Dechra and Eco Animal Health within diversified portfolios. S. M. has received conference support from numerous pharmaceutical companies. J. H. has received a travel grant funded by Wyeth pharmaceuticals, ESCMID and ISC to attend a conference. All other others—nothing to declare.


  • Carbapenemases
  • Emerging infections
  • Glycylcycline resistance

Cite this